2,242,106 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Jupiter Topco LLC

Posted by George Bondi on Aug 27th, 2026

Jupiter Topco LLC acquired a new stake in Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) during the 2nd quarter, HoldingsChannel reports. The firm acquired 2,242,106 shares of the company’s stock, valued at approximately $123,279,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in Scholar Rock in the second quarter worth $522,175,000. Redmile Group LLC lifted its position in shares of Scholar Rock by 73.7% during the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after buying an additional 3,845,775 shares during the last quarter. Orbis Allan Gray Ltd grew its stake in shares of Scholar Rock by 1,034.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after acquiring an additional 3,126,677 shares during the period. Wellington Management Group LLP grew its stake in shares of Scholar Rock by 124.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares during the period. Finally, Norges Bank purchased a new stake in Scholar Rock in the 4th quarter worth about $91,603,000. 91.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the completion of the transaction, the director directly owned 59,511 shares in the company, valued at $3,205,857.57. The trade was a 4.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $293,430.48. Following the completion of the transaction, the director directly owned 34,301 shares in the company, valued at approximately $1,848,137.88. The trade was a 13.70% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 17,149 shares of company stock worth $923,108. Company insiders own 10.30% of the company’s stock.

Scholar Rock Trading Up 3.1%

Shares of SRRK opened at $60.04 on Thursday. Scholar Rock Holding Corporation has a twelve month low of $27.07 and a twelve month high of $61.76. The stock has a market cap of $7.31 billion, a PE ratio of -17.40 and a beta of 0.69. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The business’s 50-day moving average price is $52.62 and its 200-day moving average price is $48.75.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, meeting analysts’ consensus estimates of ($0.84). During the same quarter in the prior year, the business earned ($0.98) earnings per share. On average, equities analysts forecast that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Analysts Set New Price Targets

SRRK has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $56.00 to $63.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Friday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Wedbush reissued an “outperform” rating and issued a $64.00 price target on shares of Scholar Rock in a research report on Friday, August 21st. Finally, Barclays upped their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Four analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $58.77.

View Our Latest Research Report on SRRK

About Scholar Rock

(Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).